Table 2.
Univariate and multivariate analysis of prognostic factors for overall survival in patients with pancreatic ductal adenocarcinoma
| Overall survival | ||||
|---|---|---|---|---|
| Univariate | Multivariate | |||
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| Stage† | ||||
| 0 + IA + IB | 1.0 (reference) | 1.0 (reference) | ||
| IIA | 1.159 (0.714–1.881) | 0.5490 | 5.459 (1.876–15.89) | 1.847e‐03 |
| IIB | 1.356 (0.854–2.151) | 0.1960 | 4.797 (1.692–13.60) | 3.191e‐03 |
| III + IV | 3.035 (1.301–7.081) | 0.0100 | 18.92 (5.085–70.42) | 1.156e‐05 |
| Age | 1.021 (0.995–1.048) | 0.1100 | 1.020 (0.992–1.048) | 0.075 |
| Gender | 1.107 (0.696–1.761) | 0.6660 | 1.278 (0.795–2.052) | 0.451 |
| PODXL expression | 0.345 (0.213–0.559) | 0.585e‐05 | 0.296 (0.178–0.494) | 3.126e‐06 |
| Diameter of primary tumor | 1.338 (1.176–1.524) | 1.045e‐05 | ||
| Histology‡ | 2.336 (1.359–4.017) | 0.0021 | ||
| Lymphatic invasion‡ (ly0 + ly1 or ly2 + ly3) | 1.269 (0.751–2.145) | 0.3733 | ||
| Venous invasion‡ (v0 + v1 or v2 + v3) | 1.928 (1.034–3.593) | 0.0388 | ||
| Intrapancreatic nerve invasion‡ (n0 + n1 or n2 + n3) | 1.500 (0.947–2.377) | 0.0839 | ||
†Classified according to the Union for International Cancer Control. ‡Classified according to the classification of pancreatic cancer by the Japan Pancreas Society. CI, confidence interval; HR, hazard ratio.